| abstract |
The present invention relates to a dosage form comprising a biologically active ingredient for use in the treatment or prevention of a disease in an animal or human body, wherein said treatment or prophylaxis comprises at least 50% of the biologically active ingredient in the small intestine within a pH range of 3 to 5.5. requiring release, wherein the dosage form is a) a core comprising a biologically active ingredient; b) an intermediate coating layer (ICL) on or over the core comprising an alkali agent, and c) an enteric coating layer (ECL) on or over the intermediate coating layer comprising an enteric polymer includes, The relationship between the alkali agent and the enteric polymer in the dosage form is given by the formula 5 to 95%, calculated by The intermediate coating layer (ICL) has a thickness of about 22 μm or more. |